Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Prodrug beats diclofenac

Researchers have identified one of the prodrugs of diclofenac ester as a better candidate for the treatment of chronic inflammatory diseases than its widely used parent drug diclofenac sodium1. Pro drugs are forerunners or precursors to drugs.

The researchers synthesized pro drugs 4, 5 and 6 of diclofenac ester and evaluated them in vitro and in vivo for potential use by oral delivery. The idea was to obtain an enzymatically changeable (labile) and less ulcer-causing compound than diclofenac sodium.

They found these prodrugs to be anti-inflammatory and exhibiting lesser ulcerogenic potential in experimental mice. The prodrugs also underwent quick enzymatic hydrolysis to release the parent drug diclofenac within 30 minutes to an hour in rat liver microsomes and rat plasma.

Of the three, prodrug 4 was found to be a best for the treatment of chronic inflammatory diseases.



  1. Bandgar, B. P. et al. Synthesis, Characterization, and Biological Evaluation of Novel Diclofenac Prodrugs. J. Med. Chem. (2011) doi: 10.1021/jm101095e

    Google Scholar 

Download references

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links